Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DHR 
Danaher Corporation (DHR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: DHR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $245.95
1 Year Target Price $245.95
| 19 | Strong Buy |
| 4 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.74% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 150.53B USD | Price to earnings Ratio 44.63 | 1Y Target Price 245.95 |
Price to earnings Ratio 44.63 | 1Y Target Price 245.95 | ||
Volume (30-day avg) 26 | Beta 0.76 | 52 Weeks Range 170.73 - 278.43 | Updated Date 08/15/2025 |
52 Weeks Range 170.73 - 278.43 | Updated Date 08/15/2025 | ||
Dividends yield (FY) 0.56% | Basic EPS (TTM) 4.71 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-22 | When Before Market | Estimate 1.64 | Actual 1.8 |
Profitability
Profit Margin 14.21% | Operating Margin (TTM) 20.12% |
Management Effectiveness
Return on Assets (TTM) 4.01% | Return on Equity (TTM) 6.68% |
Valuation
Trailing PE 44.63 | Forward PE 27.78 | Enterprise Value 164926365249 | Price to Sales(TTM) 6.27 |
Enterprise Value 164926365249 | Price to Sales(TTM) 6.27 | ||
Enterprise Value to Revenue 6.87 | Enterprise Value to EBITDA 24.42 | Shares Outstanding 716051968 | Shares Floating 637221470 |
Shares Outstanding 716051968 | Shares Floating 637221470 | ||
Percent Insiders 11.03 | Percent Institutions 82.83 |
Upturn AI SWOT
Danaher Corporation
Company Overview
History and Background
Danaher Corporation was founded in 1969 as DMG, Inc. and later renamed Danaher in 1984. It evolved from a real estate investment trust into a diversified technology company through strategic acquisitions and divestitures.
Core Business Areas
- Life Sciences: Offers a broad range of research tools used to analyze fundamental biological processes, including genomics, proteomics, cell biology, and microscopy.
- Diagnostics: Provides diagnostic instruments, reagents, and consumables used to analyze blood, urine, and other bodily fluids. Focuses on clinical diagnostics and anatomical pathology.
- Environmental & Applied Solutions: Provides products and services that help protect the environment and ensure the quality of water, food, and consumer products. Includes water quality analysis, product identification, and packaging integrity solutions.
Leadership and Structure
Rainer M. Blair is the President and CEO. Danaher operates under a decentralized structure with various operating companies managed under the Danaher Business System (DBS).
Top Products and Market Share
Key Offerings
- Cytiva (Bioprocessing): Cytiva provides technologies and services that enable the research, development, and manufacturing of biopharmaceuticals. Competitors include Thermo Fisher Scientific (TMO), Sartorius (SRT.F), and Merck KGaA (MRK.DE). Market share data is difficult to obtain precisely, but Cytiva is a major player in the bioprocessing market estimated to be a significant percentage.
- Beckman Coulter Diagnostics: Beckman Coulter Diagnostics offers a comprehensive range of diagnostic instruments and reagents. Competitors include Roche (ROG.SW), Abbott (ABT), and Siemens Healthineers (SHL.DE). Market share is a significant portion of the global IVD market, but precise data is not readily available.
- Hach (Water Quality): Hach provides water quality analysis and testing solutions for various applications. Competitors include Xylem (XYL), and other water quality monitoring companies. Hach holds a leading position within the water quality analysis market.
Market Dynamics
Industry Overview
The industries Danaher operates in are characterized by continuous innovation, increasing regulatory requirements, and growing demand for advanced technologies in healthcare, environmental monitoring, and bioprocessing.
Positioning
Danaher is positioned as a leading provider of high-tech instruments and consumables. Its competitive advantages include its strong brands, the Danaher Business System, and its diversified portfolio.
Total Addressable Market (TAM)
TAM is estimated to be in the hundreds of billions of dollars across its various segments. Danaher is well-positioned to capture a significant portion of this TAM through its strategic acquisitions and organic growth initiatives.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Diversified business portfolio
- Effective Danaher Business System (DBS)
- Consistent acquisition strategy
- Global presence
Weaknesses
- High reliance on acquisitions for growth
- Exposure to cyclical industries
- Integration risks associated with acquisitions
- Debt levels can be elevated post-acquisition
Opportunities
- Growing demand for biopharmaceuticals
- Increasing regulatory focus on water quality
- Expansion in emerging markets
- Technological advancements in diagnostics and life sciences
Threats
- Economic downturns
- Increased competition
- Regulatory changes
- Disruptive technologies
Competitors and Market Share
Key Competitors
- TMO
- ABT
- ROCHE.SW
- SI
- XYL
Competitive Landscape
Danaher's competitive advantages include its strong brands and DBS. Disadvantages include its reliance on acquisitions and exposure to cyclical industries.
Major Acquisitions
Aldevron
- Year: 2021
- Acquisition Price (USD millions): 9600
- Strategic Rationale: Expanded Danaher's capabilities in the genomic medicine space.
Eppendorf Bioprocess Business
- Year: 2024
- Acquisition Price (USD millions): 750
- Strategic Rationale: To strengthen Danaher's Biotechnology business segment and to expand in bioprocessing markets.
Growth Trajectory and Initiatives
Historical Growth: Danaher has achieved significant growth through organic initiatives and strategic acquisitions.
Future Projections: Analyst estimates suggest continued growth for Danaher, driven by favorable industry trends and the company's strategic initiatives.
Recent Initiatives: Recent initiatives include new product launches, acquisitions, and investments in research and development.
Summary
Danaher is a strong, diversified technology company with a proven track record of growth through strategic acquisitions and operational excellence. The Danaher Business System provides a competitive advantage. A weakness is high debt levels. Ongoing innovation is key.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Market Research Reports
- Analyst Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change. The accuracy of market share data cannot be guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Danaher Corporation
Exchange NYSE | Headquaters Washington, DC, United States | ||
IPO Launch date 1979-01-05 | President, CEO & Director Mr. Rainer M. Blair | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 61000 | Website https://www.danaher.com |
Full time employees 61000 | Website https://www.danaher.com | ||
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a partnership with AstraZeneca PLC to develop and commercialize diagnostic tools and tests. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.